CRSP
CRISPR Therapeutics AG
Stock
$55.43−0.01 (−0.02%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13M | $3.5M | $37M | $371M | $1.2M | $915M | $719K | $290M | $3.1M | $41M | $5.2M | $247K |
| R&D | $278M | $285M | $310M | $387M | $462M | $341M | $221M | $179M | $114M | $70M | $42M | $13M |
| Operating income | −$534M | −$665M | −$467M | −$223M | −$673M | $374M | −$354M | $47M | −$159M | −$65M | −$68M | −$26M |
| Non-operating income | $86M | $87M | $104M | $72M | $23M | $6.0M | $6.4M | $21M | −$5.5M | −$2.0M | $45M | −$92K |
| Pretax income | −$448M | −$578M | −$363M | −$151M | −$651M | $380M | −$348M | $67M | −$164M | −$67M | −$23M | −$26M |
| Taxes | $3.0M | $3.6M | $3.6M | $2.9M | −$325K | $1.9M | $809K | $448K | $553K | $1.7M | $459K | −$318K |
| Net income | −$451M | −$582M | −$366M | −$154M | −$650M | $378M | −$349M | $67M | −$165M | −$68M | −$23M | −$26M |
| Diluted EPS | −$4.76 | −$6.47 | −$4.34 | −$1.94 | −$8.36 | $4.70 | −$5.29 | $1.17 | −$3.44 | −$1.71 | −$1.89 | −$5.06 |
| Diluted shares | — | 89.9M | 84.4M | 79.2M | 77.7M | 80.4M | 65.9M | 56.9M | 48.0M | 40.1M | 12.3M | 5.0M |
| Revenue growth | — | −90.6% | −89.9% | +30,885.5% | −99.9% | +127,154.9% | −99.8% | +9,169.8% | −92.4% | +693.9% | +1,990.7% | — |
| Operating margin | −3,990.0% | −18,933.6% | −1,250.4% | −60.0% | −56,190.4% | 40.8% | −49,295.5% | 16.1% | −5,087.8% | −157.7% | −1,319.3% | −10,416.6% |
| Net margin | −3,368.7% | −16,569.8% | −981.5% | −41.4% | −54,271.7% | 41.3% | −48,520.9% | 23.1% | −5,281.1% | −166.7% | −448.8% | −10,325.1% |